首页> 外文期刊>BMC Cancer >Extracellular vesicles-derived microRNA-222 promotes immune escape via interacting with ATF3 to regulate AKT1 transcription in colorectal cancer
【24h】

Extracellular vesicles-derived microRNA-222 promotes immune escape via interacting with ATF3 to regulate AKT1 transcription in colorectal cancer

机译:细胞外囊泡衍生的microRNA-222通过与ATF3相互作用来调节结直肠癌中的AKT1转录来促进免疫逃逸

获取原文
           

摘要

Immunotherapy has been recently established as a new direction for the treatment of colorectal cancer (CRC), a gastrointestinal cancer. In this investigation, we aimed to expound how the posttranscriptional regulation modulated by microRNA-222 (miR-222) from mesenchymal stem cells-derived extracellular vesicles (MSC-EVs) affected the AKT pathway and the immune escape in CRC. CRC cell malignant phenotype, including proliferation, migration, invasion, and apoptosis, was firstly detected after co-culture with MSC-EVs. miRNAs with differential changes in CRC cells before and after EVs treatment were filtered by microarray analysis. miR-222 was then downregulated to examine its role in CRC cells in response to EVs. Cells were implanted in mice to induce xenograft tumors, and infiltrating T cells was assessed by immunohistochemistry. The mRNA microarray was used to screen target genes, followed by rescue experiments. ChIP and western blot were conducted to validate the downstream biomolecule of ATF3. After treatment of CRC cells with MSC-EVs, the expression of miR-222 was upregulated, and cell activity was increased. Inhibition of miR-222 decreased CRC malignant aggressiveness in vitro and reduced tumorigenesis and immune escape in vivo. miR-222 targeted and bound to ATF3. Downregulation of ATF3 enhanced CRC cell malignant aggressiveness, tumorigenic capacity and immune escape. Mechanistically, ATF3 inhibited AKT1 transcription and mediated the AKT pathway. MSC-EVs carry miR-222 to promote CRC cell malignant aggressiveness and immune escape. miR-222 targets and binds to ATF3, which inhibits AKT1 transcriptional activity and thereby mediates the AKT pathway.
机译:最近被确定为治疗结直肠癌(CRC),胃肠癌的新方向。在这项调查中,我们旨在阐述Microrna-222(miR-222)从间充质干细胞衍生的细胞外囊泡(Msc-evs)调节的后颅调节如何影响AKT途径和CRC中的免疫逸出。在与MSC-EVS共同培养后首先检测到CRC细胞恶性表型,包括增殖,迁移,侵袭和凋亡。通过微阵列分析过滤EVS处理之前和之后CRC细胞的差异变化的miRNA。然后下调miR-222,以响应EVS检查其在CRC细胞中的作用。将细胞植入小鼠中以诱导异种移植肿瘤,并通过免疫组织化学评估渗透T细胞。 MRNA微阵列用于筛选靶基因,然后进行救援实验。进行芯片和蛋白质印迹以验证ATF3的下游生物分子。用MSC-EV处理治疗CRC细胞后,上调miR-222的表达,并且增加细胞活性。抑制miR-222在体外减少了CRC恶性侵袭性,减少了体内肿瘤鉴定和免疫逸出。 miR-222靶向并绑定到ATF3。 ATF3的下调增强了CRC细胞恶性侵略性,致瘤能力和免疫逸出。机械地,ATF3抑制AKT1转录并介导AKT途径。 MSC-EVS携带miR-222,以促进CRC细胞恶性侵袭性和免疫逃逸。 miR-222靶向并结合ATF3,其抑制AKT1转录活性,从而介导AKT途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号